Otsuka & Lundbeck v. Mylan & Viatris: Aripiprazole Patent Dispute Dismissed Without Prejudice
Otsuka Pharmaceutical and H. Lundbeck asserted eight patents covering controlled-release injectable and oral aripiprazole formulations against Mylan and Viatris in Delaware. After 591 days of litigation, all claims and counterclaims were dismissed without prejudice by stipulation, with each side bearing its own costs — suggesting the parties reached a private resolution.
Eight-Patent Aripiprazole ANDA Battle Ends by Stipulated Dismissal in Delaware
On October 17, 2022, Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck AS filed a patent infringement action in the U.S. District Court for the District of Delaware — Case No. 1:22-cv-01367 — against Mylan NV, Mylan Pharmaceuticals Inc., and Viatris Inc. The complaint asserted eight U.S. patents covering multiple aspects of aripiprazole technology, including controlled-release sterile injectable formulations, low-hygroscopic drug substance manufacturing processes, and dosing methods for patients with impaired CYP2D6 or CYP3A4 enzyme function. The asserted patents span application dates ranging from the mid-2000s through the early 2020s, reflecting a layered IP portfolio built around the branded antipsychotic franchise.
The case closed on May 30, 2024, when the parties filed a joint stipulation dismissing all remaining claims and counterclaims without prejudice, with each side bearing its own attorneys’ fees and costs. Judge Jennifer L. Hall entered the dismissal and specifically retained jurisdiction to adjudicate any issues arising from the settlement of the action — standard language consistent with an underlying confidential settlement agreement. A dismissal without prejudice technically preserves each party’s right to refile, though the retained-jurisdiction clause suggests the parties memorialised binding terms outside the public record.
The 591-day duration is consistent with an ANDA-triggered Hatch-Waxman case that ran through at least some substantive phase before the parties negotiated an exit. The without-prejudice characterisation, combined with the absence of any cost-shifting, means neither side secured a formal adjudication on the merits. What drove resolution — whether a licensing agreement, an agreed launch date, or commercial concessions — remains undisclosed. The court’s retained jurisdiction clause is a notable signal that enforceable settlement terms were reached, even if their content is shielded from public view.
Filing to Dismissed without Prejudice in 591 days
591 days — slightly above the median ANDA/Hatch-Waxman district court disposition in Delaware
Dismissed without prejudice: what the stipulated exit means for both sides
Stipulated dismissal without prejudice — no merits ruling
A dismissal without prejudice means the court issued no judgment on whether the asserted patents are valid or infringed. The parties jointly requested the exit, and the court granted it while retaining jurisdiction over any settlement disputes. This is a common structure in Hatch-Waxman cases where the innovator and generic reach a licensing or market-entry agreement: the litigation is taken off the docket without either side admitting liability or conceding invalidity.
No merits adjudicationWithout prejudice: refiling remains technically available
A dismissal without prejudice preserves each party’s right to refile claims under the same patents. In practice, the court’s express retention of jurisdiction over settlement-related issues strongly suggests binding terms were reached privately. If Mylan/Viatris breach any agreed conditions — such as an authorised launch date or royalty obligation — Otsuka and Lundbeck could return to this court without starting fresh litigation. The public record does not disclose whether any licence, entry date, or other commercial terms were agreed.
Refiling technically preservedPatents remain unadjudicated — enforceability intact
Otsuka and Lundbeck avoided any invalidity or non-infringement ruling against their eight-patent portfolio. The aripiprazole patents survive with no estoppel or collateral consequences from this proceeding. If the underlying settlement includes a future authorised launch date, the innovators will have effectively converted litigation risk into a defined commercial framework — a common and commercially rational outcome for branded pharmaceutical IP portfolios facing generic entry.
Patent portfolio intactMylan/Viatris avoided an adverse validity ruling — at a cost
Mylan and its Viatris affiliates exit without a court finding of invalidity or non-infringement, which preserves their legal positions. However, the cost-neutrality clause — each side bears its own fees — combined with a without-prejudice dismissal typically signals that the generic challenger agreed to some form of market-entry restriction or delay. The precise terms remain confidential. Other generic filers seeking ANDA approval for aripiprazole products should note that this case did not clear the patent landscape.
No invalidity finding securedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Otsuka Pharmaceutical Co., Ltd. | Company | Global pharmaceutical innovator — holder of US11400087B2 and 7 further aripiprazole patentsSearch in Eureka ↗ |
| Co-Plaintiff | H. Lundbeck, AS | Individual | Search in Eureka ↗ |
| Defendant | Mylan, NV | Company | Generic pharmaceutical manufacturer and its affiliates (Mylan NV, Mylan Pharmaceuticals Inc., Viatris Inc.)Search in Eureka ↗ |
| Co-Defendant | Mylan Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Viatris, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Otsuka Pharmaceutical Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Andrew Mark Moshos | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Bindu Ann George Palapura | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Christine Dealy Haynes | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | David Ellis Moore | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Frederick L. Cottrell , III | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant counsel | Jason James Rawnsley | Attorney | Counsel for Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Potter, Anderson & Corroon LLP | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Defendant law firm | Richards, Layton & Finger, PA | Law Firm | Representing Mylan, NVSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s language — ‘dismissal, without prejudice, of all remaining claims and counterclaims’ with ‘parties to bear their own costs’ — is consistent with a negotiated commercial resolution rather than a concession by either side. The phrase ‘all remaining claims and counterclaims’ suggests prior claims may have been resolved or narrowed earlier in the proceeding. The court’s express retention of jurisdiction to adjudicate issues arising from ‘the settlement of this action’ is the most legally significant element: it confirms a settlement instrument exists and gives the court supervisory authority if either party alleges breach, without requiring the settlement terms to be made public.
US11400087B2 and 7 further patents — aripiprazole formulations and dosing methods
The eight asserted patents collectively cover the full commercial lifecycle of aripiprazole as a pharmaceutical product. US11400087B2 and US10980803B2 relate to controlled-release sterile injectable formulations — the technology underlying long-acting injectable antipsychotic products. US10525057B2 and US8722679B2 address low-hygroscopic drug substance manufacturing and pharmacogenomic dosing for patients with impaired CYP2D6 or CYP3A4 metabolism. The remaining patents — US8338427B2, US8399469B2, US7807680B2, and US11154553B1 — cover aripiprazole administration methods. Application dates span from 2006 (US10/968482) to 2021 (US17/304606 and US17/304610), reflecting continuous portfolio development.
From a strategic standpoint, this portfolio is designed to create overlapping exclusivity across the compound, its physical form, its manufacture, and its clinical use — a classic innovator layering strategy. The inclusion of pharmacogenomic method patents is commercially significant: even after composition patents expire, method-of-treatment patents tied to patient subpopulations can sustain exclusivity if generic labels must include equivalent dosing instructions. Any company seeking to commercialise an aripiprazole generic — particularly an injectable extended-release form — faces a multi-front invalidity and non-infringement analysis across all eight patent families before assuming a clear path to market.
Should you run an FTO against the aripiprazole patent portfolio asserted in this case?
Any pharmaceutical company developing, manufacturing, or seeking ANDA approval for an aripiprazole product — particularly controlled-release injectable formulations or oral products with pharmacogenomic dosing labelling — should conduct a structured freedom-to-operate analysis against all eight patents asserted in this case. The without-prejudice dismissal means none of these patents were invalidated or found not infringed. US11400087B2 and US11154553B1 were filed as recently as 2021 and carry patent terms potentially extending into the late 2030s, creating long-dated risk for generic and biosimilar pipeline planning.
PatSnap Eureka’s FTO Search Agent can map each of the eight asserted patent numbers against your product formulation, process, and proposed label language. The tool identifies claim overlap, flags forward citations from each patent family, and surfaces any inter partes review history or prosecution disclaimers that affect claim scope. For teams preparing ANDA filings or paragraph IV certifications targeting aripiprazole products, a systematic Eureka FTO audit across this portfolio is a recommended first step before committing to development or regulatory timelines.
Run a freedom-to-operate analysis on US11400087B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman aripiprazole and antipsychotic ANDA patent cases
Explore related ANDA infringement cases in the District of Delaware involving aripiprazole formulations, injectable antipsychotics, and multi-patent pharmaceutical portfolios.
What this case signals for the branded pharmaceutical IP landscape
Eight-patent Hatch-Waxman cases settled without prejudice in Delaware reveal how innovators use layered portfolios to control generic entry timing.
Layered aripiprazole portfolios create durable generic entry barriers
Otsuka and Lundbeck assembled patents spanning formulation, manufacturing process, and patient-specific dosing — covering injectable and oral forms. This multi-patent strategy means any generic entrant must design around or challenge each layer individually. A single without-prejudice dismissal does not clear the landscape; companies pursuing aripiprazole ANDAs should audit all eight asserted patents independently.
Retained jurisdiction clauses signal enforceable settlement terms
When a Delaware district court retains jurisdiction post-dismissal, it strongly suggests the parties executed a binding settlement — potentially including authorised launch dates, royalties, or co-promotion terms. Competitors and investors tracking generic aripiprazole market entry should treat this case as a signal of a negotiated timeline rather than an open competitive window.
Otsuka v Mylan — key questions answered
Otsuka Pharmaceutical and H. Lundbeck asserted eight U.S. patents: US11400087B2, US10525057B2, US8722679B2, US8338427B2, US8399469B2, US10980803B2, US7807680B2, and US11154553B1. The patents collectively cover controlled-release injectable aripiprazole formulations, low-hygroscopic drug substance manufacturing, and pharmacogenomic dosing methods for patients with impaired CYP2D6 or CYP3A4 enzyme function.
The parties filed a joint stipulation of dismissal without prejudice on or before May 30, 2024. The dismissal was not accompanied by any merits ruling. The court retained jurisdiction over settlement-related issues, strongly suggesting the parties reached a confidential settlement agreement — a common resolution structure in Hatch-Waxman ANDA litigation where innovators and generics negotiate authorised entry dates or licensing terms.
No. A dismissal without prejudice does not constitute an invalidity or non-infringement finding. The eight asserted patents remain in force. The court’s retained jurisdiction clause suggests binding settlement terms — which may include restrictions on market entry — were agreed privately. Companies seeking to commercialise generic aripiprazole should conduct independent FTO analysis across all eight patent families and should not treat this dismissal as a cleared patent landscape.
Method-of-treatment patents tied to patient subpopulations — such as US8722679B2 covering aripiprazole dosing for patients with impaired CYP2D6 enzyme function — can remain enforceable after composition patents expire. If a generic label includes dosing guidance for the same patient subpopulation, the generic manufacturer may face induced infringement exposure. This makes label carve-out analysis critical for any ANDA applicant targeting aripiprazole products.
Otsuka and Lundbeck were represented by Ashby & Geddes PC, with attorneys Andrew Colin Mayo and Steven J. Balick appearing on record. Mylan and Viatris were represented by Potter, Anderson & Corroon LLP and Richards, Layton & Finger PA, with attorneys including Frederick L. Cottrell III, David Ellis Moore, Bindu Ann George Palapura, and others appearing for the defendants.
PatSnap Eureka searches patents and litigation data to answer instantly.